Cambridge-based biotechnology company, Prime Medicine, Inc. (Nasdaq: PRME), has successfully completed its underwritten upsized public offering, generating significant funds amounting to approximately $161.0 million. The offering comprised of 22,560,001 shares of Prime Medicine’s common stock, including the underwriters’ full exercise of their option to purchase an additional 3,360,000 shares. To some investors, Prime Medicine also offered pre-funded warrants to purchase 3,200,005 shares of common stock.
The public offering was priced at $6.25 per share, with the pre-funded warrants priced at $6.24999 per warrant, which effectively ensured that the per share public offering price of the common stock remained unchanged after deducting the $0.00001 per share exercise price for each pre-funded warrant. All the shares of common stock and pre-funded warrants were exclusively sold by Prime Medicine.
This successful offering marks an important milestone for Prime Medicine, demonstrating the significant interest and confidence of investors in the company’s promising one-time curative genetic therapies. The funds raised from this public offering will provide Prime Medicine with the necessary resources to further advance research and development in this groundbreaking field, ultimately offering hope to patients suffering from genetic disorders.
With the inclusion of the underwriters’ option to purchase additional shares, Prime Medicine has not only secured additional capital but has also bolstered investor sentiment by showcasing its potential for growth and expansion.
The completion of this upsized public offering solidifies Prime Medicine’s position as a frontrunner in the biotechnology industry. Harnessing the power of genetic therapies, Prime Medicine aims to revolutionize the treatment paradigm for genetic diseases, providing patients with life-changing solutions.
Prime Medicine Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares
Comments